Clinical Data for OrbusNeich’s Combo Dual Therapy Stent™ Set for Presentation at EuroPCR 2012

Twelve-Month Results from REMEDEE Trial Will Be Featured During Oral Scientific Sessions; Optical Coherence Tomography (OCT) Data for Combo and Genous Stents Assess Early Healing Driven by Endothelial Progenitor Cell (EPC) Capture

HONG KONG, May 8, 2012 – OrbusNeich today announced that clinical data for the Combo Dual Therapy Stent will be presented at EuroPCR 2012 in Paris. The oral scientific sessions will feature the 12-month results from REMEDEE (Randomized Evaluation of an abluminal sirolimus coatED bio-Engineered stEnt), a randomized clinical trial of the Combo Stent. In addition, interim data from the EGO-COMBO study assessing early healing of Combo by OCT will be presented alongside the study design for REMEDEE OCT.

Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will give the presentation “Twelve-month results of the REMEDEE trial: a
randomized comparison of a sirolimus-eluting CD34 antibody-coated stent versus a paclitaxel-eluting stent in patients” during the session “Comparison of outcomes between DES (part I)” at 16:35 CET on Tuesday, May 15, in Room 342B at the Palais des Congrès de Paris.

The REMEDEE trial was designed to demonstrate the safety and effectiveness of the Combo Dual Therapy Stent compared to the TAXUS® Liberté® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective was measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure. The trial included 183 patients at sites in Asia, Australia, Europe and South America.

**Other Scientific Sessions of Note**

**OCT assessment of vascular responses to stent designs**

17:00 CET, Tuesday, May 15: Room 242A

- Prof. Stephen W.L. Lee, M.D., chief of cardiology, professor and senior consultant, Department of Medicine, Queen Mary Hospital, University of Hong Kong, will present “Evaluation of early healing of endothelial progenitor cell capturing sirolimus-eluting stent by optical coherence tomography: the EGO-COMBO study, first follow-up result.”

- Ulf Landmesser, M.D., Ph.D., of the Cardiovascular Center, University Hospital of Zürich, Switzerland, will present the study design for “The REMEDEE Optical Coherence Tomography study.”

**Managing difficult complications**

16:30 CET, Wednesday, May 16: Room 341

- Prof. Lee will present OCT data for the Genous™ Stent during his talk “OCT guided management of very late stent thrombosis: use of endothelial progenitor cell capturing stents.”

**Cardiovascular Innovation Pipeline Sessions**
Novel devices
9:00 CET, Thursday, May 17, Room 351

- Robert Cottone, vice president, intellectual property and technologies at OrbusNeich, will present the following: “Blended PLLA scaffold with partitioned sirolimus and endothelial progenitor cell capture.”

Drug-eluting stents
10:30 CET, Thursday, May 17, Room 241

- Erik Ligtenberg, director of research and development at OrbusNeich, will introduce the Combo Dual Therapy Stent.

Poster Sessions
Tuesday, May 15, through Friday, May 18, in Hall Ternes (Level 1)

- **Abstract ID: 568** - Serial virtual histology IVUS in a prospective randomized comparison of an abluminal sirolimus-coated bioengineered stent compared to a paclitaxel-coated stent

- **Abstract ID: 576** - Optical coherence tomography findings after coronary implantation of a combined sirolimus-eluting and endothelial progenitor cell capture stent compared to a paclitaxel-eluting stent: results from the REMEDEE first-in-man trial

About the Genous Technology

**Genous** is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents.
and is supported by data from more than 7,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients that are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich’s YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

###

Note: OrbusNeich will display its stents at booth N6 at EuroPCR 2012.